Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.61 |
| ▸ | F2 | P00734 | 2/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | C1S | P09871 | 3/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28553423 | 1.00 | PRSS1 (0.61) | PRSS1PRSS2PRSS3F2PARP1 | |
| SCHEMBL2687704 | 0.98 | PARP1 (0.63) | PRSS1PRSS2PRSS3F2PARP1 | |
| Formic Acid SCHEMBL38652409 | 0.88 | PARP1 (0.58) | PRSS1PRSS2PRSS3F2PARP1 | |
| Sulfuric Acid SCHEMBL38652318 | 0.88 | PARP1 (0.58) | PRSS1PRSS2PRSS3F2PARP1 | |
| Acetic Acid SCHEMBL38652070 | 0.88 | PARP1 (0.63) | PRSS1PRSS2PRSS3F2PARP1 | |
| SCHEMBL17774314 | 0.86 | PRSS1 (0.69) | PRSS1PRSS2PRSS3F2PARP1 | |
| Hydrochloric Acid SCHEMBL28253026 | 0.84 | PRSS1 (0.74) | PRSS1PRSS2PRSS3F2PLG | |
| Hydrochloric Acid SCHEMBL28555629 | 0.84 | PRSS1 (0.74) | PRSS1PRSS2PRSS3F2PLG | |
| Trifluoroacetic Acid SCHEMBL38651965 | 0.82 | PARP1 (0.56) | PRSS1PRSS2PRSS3F2PARP1 | |
| SCHEMBL15547311 | 0.81 | PRSS1 (0.70) | PRSS1PRSS2PRSS3F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947854-A | Preparation method of imidazo [2,1-a ] isoquinoline compound | 赣南师范大学 | 2023-10-27 | — | — | CN | claimed |
| CN-114394957-A | Preparation method of MET inhibitor terbacitinib hydrochloride | 武汉九州钰民医药科技有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-116947854-A | Preparation method of imidazo [2,1-a ] isoquinoline compound | 赣南师范大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114394957-A | Preparation method of MET inhibitor terbacitinib hydrochloride | 武汉九州钰民医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114394957-A | Preparation method of MET inhibitor terbacitinib hydrochloride | 武汉九州钰民医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-106674131-B | A method of synthesis polysubstituted pyrimidine heterocyclic compound | 华南理工大学 | 2019-08-20 | — | — | CN | disclosed |
| CN-106316885-B | A kind of preparation method of 3- [5- (2- fluorophenyl) -1,2,4- oxadiazoles -3- base] benzoic acid | 普济生物科技（台州）有限公司 | 2019-02-12 | — | — | CN | disclosed |
| CN-106674131-A | Method for compounding polysubstituted pyrimidine heterocyclic compound | 华南理工大学 | 2017-05-17 | — | — | CN | disclosed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-4168964-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1979-09-25 | — | — | US | disclosed |
| US-3968213-A | 4-HYDROXY-5-CARBOXY PYRIMIDINES | PFIZER INC. (US) | 1976-07-06 | — | — | US | disclosed |
| US-3957784-A | ANTIALLERGY AGENTS | PFIZER INC. (US) | 1976-05-18 | — | — | US | disclosed |
| US-3940395-A | CNS DEPRESSANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | PARP1 143/4885PRSS1 502/4885PRSS2 2182/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | PARP1 1383/4885PRSS1 34/4885PRSS2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.